Osteonecrosis Following Chemotherapy for Leukemia

Pieters, Rob; Schans-Dop, Annemiek M van der; Brenk, Andrzej; Amerongen, A H Taets van

doi:10.1111/j.1600-0609.1989.tb00295.x

Cited by 8 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osteonecrosis (ON) is well-recognized as one of these complications [1,2]. Symptomatic ON (sON) has been reported in 1-17% of children with ALL in remission [2][3][4][5][6] although an incidence of up to 72% of asymptomatic ON has been found with systematic screening by magnetic resonance imaging (MRI) [5,7,8].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia

Leblicq

Laverdière

Décarie

et al. 2012

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia

Leblicq

Laverdière

Décarie

et al. 2012

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Osteonecrosis (ON) is well‐recognized as one of these complications 1, 2. Symptomatic ON (sON) has been reported in 1–17% of children with ALL in remission 2–6 although an incidence of up to 72% of asymptomatic ON has been found with systematic screening by magnetic resonance imaging (MRI) 5, 7, 8.…”

Section: Introductionmentioning

confidence: 99%

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma

Calabrò

Lorusso

Rosati

et al. 2009

Cancer

View full text Add to dashboard Cite

Background Osteonecrosis (ON) is a severe complication of acute lymphoblastic leukemia (ALL) treatments. Recent studies suggest that bisphosphonates might reduce pain and loss of motor function in patients with ON. We assessed the effects of pamidronate compared to standard care in patients with symptomatic ON (sON) and studied whether steroids might be continued after diagnosis of ON in some patients. Methods We evaluated 17 patients with sON as complication of primary ALL treatment between 2000 and 2008. Fourteen patients were treated with pamidronate. Mobility and pain control were monitored in all patients. Affected joints were classified by magnetic resonance imaging (MRI) at ON diagnosis and after 6–72 months. Results Out of 220 patients with ALL, 17 (7.7%) patients developed sON. The median age at ALL diagnosis was 11 years (range: 2.7–16.6 years) and sON occurred a median of 13.4 months (range: 2.5–34 months) after ALL diagnosis. Affected joints were hip, knee and ankle. MRI scans showed 7 severe, 4 moderate, and 6 mild ON lesions. Fourteen patients showed improvement in pain (77% of patients) and motor function (59% of patients), even though corticoids were reintroduced in 4 patients. MRI demonstrated improvement, stability or worsening in 6, 3, and 5 cases, respectively. Conclusions Pamidronate seems to be effective in the management of pain and motor function recovery in sON. Further studies are needed to provide evidence as to whether bisphosphonates can be recommended for the treatment or the prevention of ON in childhood ALL patients. Pediatr Blood Cancer 2013; 60: 741–747. © 2012 Wiley Periodicals, Inc.

show abstract